Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Puma's Neratinib SUMMIT Study Shows Potential & Pitfalls Of Precision Medicine

Executive Summary

"Basket trial" design allowed Puma to identify certain cohorts for further study, but also missed in areas where neratinib was expected to work.


Related Content

Master Protocols In Practice
Loxo Sees Larotrectinib As Model Form Of Oncology Drug Development
Keytruda Approval Opens New Routes For Immuno-Oncology
It's Not All About IO: Seven Drugs To Watch At ASCO
Roche Relief As APHINITY Trial Boosts Outlook On Its Oncology Business
I-SPY Graduates: Where Are They Now?
Puma Plummets On Another Neratinib NDA Delay
Genomics-Driven Trials Built To Be Fast And Flexible


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts